Hien Thi Thu Nguyen1, Reinhard Wimmer2, Vang Quy Le3, Henrik Bygum Krarup4,5,6. 1. Department of Molecular Diagnostics, Aalborg University Hospital, Reberbansgade 15, 9000, Aalborg, Denmark. 2. Department of Chemistry and Bioscience, Aalborg University, Aalborg, Denmark. 3. CLAAUDIA, Aalborg University, Aalborg, Denmark. 4. Department of Molecular Diagnostics, Aalborg University Hospital, Reberbansgade 15, 9000, Aalborg, Denmark. h.krarup@rn.dk. 5. Department of Medical Gastroenterology, Aalborg University Hospital, Aalborg, Denmark. h.krarup@rn.dk. 6. Clinical Institute, Aalborg University, Aalborg, Denmark. h.krarup@rn.dk.
Abstract
INTRODUCTION: Chronic hepatitis B (CHB) affects 257 million individuals worldwide with an annual estimated mortality rate of 880,000 individuals. Accurate diagnosis of the stage of disease is difficult, and there is considerable uncertainty concerning the optimal point in time, when treatment should be started. OBJECTIVES: By analyzing and comparing the metabolomes of patients at different stages of CHB and comparing them to healthy individuals, we want to determine the metabolic signature of disease progression and develop a more accurate metabolome-based method for diagnosis of disease progression ultimately giving a better basis for treatment decisions. METHODS: In this study, we used the combination of transient elastography and serum metabolomics of 307 serum samples from a group of 90 patients with CHB before and under treatment (with a follow-up time up to 10 years) at different progression stages over the clinical phases and 43 healthy controls.. RESULTS: Our data show that the metabolomics approach can successfully discover CHB changing from the immune tolerance to the immune clearance phase and show distinctive metabolomes from different medical treatment stages. Perturbations in ammonia detoxification, glutamine and glutamate metabolism, methionine metabolism, dysregulation of branched-chain amino acids, and the tricarboxylic acid (TCA) cycle are the main factors involved in the progression of the disease. Fluctuations increasing in aspartate, glutamate, glutamine, methionine and 13 other metabolites are fingerprints of progression. CONCLUSIONS: The metabolomics approach may expand the diagnostic armamentarium for patients with CHB. This method can provide a more detailed decision basis for starting medical treatment.
INTRODUCTION:Chronic hepatitis B (CHB) affects 257 million individuals worldwide with an annual estimated mortality rate of 880,000 individuals. Accurate diagnosis of the stage of disease is difficult, and there is considerable uncertainty concerning the optimal point in time, when treatment should be started. OBJECTIVES: By analyzing and comparing the metabolomes of patients at different stages of CHB and comparing them to healthy individuals, we want to determine the metabolic signature of disease progression and develop a more accurate metabolome-based method for diagnosis of disease progression ultimately giving a better basis for treatment decisions. METHODS: In this study, we used the combination of transient elastography and serum metabolomics of 307 serum samples from a group of 90 patients with CHB before and under treatment (with a follow-up time up to 10 years) at different progression stages over the clinical phases and 43 healthy controls.. RESULTS: Our data show that the metabolomics approach can successfully discover CHB changing from the immune tolerance to the immune clearance phase and show distinctive metabolomes from different medical treatment stages. Perturbations in ammonia detoxification, glutamine and glutamate metabolism, methionine metabolism, dysregulation of branched-chain amino acids, and the tricarboxylic acid (TCA) cycle are the main factors involved in the progression of the disease. Fluctuations increasing in aspartate, glutamate, glutamine, methionine and 13 other metabolites are fingerprints of progression. CONCLUSIONS: The metabolomics approach may expand the diagnostic armamentarium for patients with CHB. This method can provide a more detailed decision basis for starting medical treatment.
Authors: J H Horowitz; E B Rypins; J M Henderson; S B Heymsfield; S D Moffitt; R P Bain; R K Chawla; J C Bleier; D Rudman Journal: Gastroenterology Date: 1981-10 Impact factor: 22.682
Authors: Caroline J Sands; Indra N Guha; Michael Kyriakides; Mark Wright; Olaf Beckonert; Elaine Holmes; William M Rosenberg; Muireann Coen Journal: Am J Gastroenterol Date: 2014-12-23 Impact factor: 10.864
Authors: Jeremy K Nicholson; Elaine Holmes; James M Kinross; Ara W Darzi; Zoltan Takats; John C Lindon Journal: Nature Date: 2012-11-15 Impact factor: 49.962